Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue based cancer diagnostics, and a frontrunner in diabetes management. Founded in , Roche continues to search for better ways to prevent, diagnose and treat diseases and make sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life saving antibiotics, antimalarials and chemotherapy. In , the Roche Group employed about , people worldwide, invested . billion Swiss francs in R amp D and posted sales of . billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com
Quote | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
Last: | $34.43 |
---|---|
Change Percent: | 0.98% |
Open: | $34.3 |
Close: | $34.43 |
High: | $34.512 |
Low: | $34.29 |
Volume: | 1,649,918 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-07-01 11:07:23 ET Summary Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treating retinal diseases, with potential to become a mar...
Message Board Posts | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RHHBY News Article - New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety | whytestocks | investorshangout | 07/11/2022 3:45:52 PM |
$25 coming soon!!! | OptimusPrime555 | investorshub | 06/13/2022 2:14:35 PM |
whytestocks: $RHHBY News Article - Data at the 2022 ASCO Annual Meeting Highlight Genentech's Contin | whytestocks | investorshangout | 05/24/2022 2:50:51 PM |
whytestocks: $RHHBY News Article - Roche launches the first infectious disease tests and cobas omni | whytestocks | investorshangout | 12/15/2021 5:55:50 PM |
$rhhby $40.45 v -0.2 (-0.49%) | Taurus69 | investorshub | 03/28/2021 6:39:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
Roche receives FDA clearance on its digital pathology solution for diagnostic use PR Newswire The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling patho...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a muc...